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Abstract
microRNAs are small, non-coding RNAs that influence diverse biological functions through the
repression of target genes during normal development and pathological responses. Widespread use
of microRNA arrays to profile microRNA expression has indicated that the levels of many
microRNAs are altered during development and disease. These findings have prompted a great deal
of investigation into the mechanism and function of microRNA-mediated repression. However, the
mechanisms which govern the regulation of microRNA biogenesis and activity are just beginning to
be uncovered. Following transcription, mature microRNA are generated through a series of
coordinated processing events mediated by large protein complexes. It is increasingly clear that
microRNA biogenesis does not proceed in a 'one-size-fits-all' manner. Rather, individual classes of
microRNAs are differentially regulated through the association of regulatory factors with the core
microRNA biogenesis machinery. Here, we review the regulation of microRNA biogenesis and
activity, with particular focus on mechanisms of post-transcriptional control. Further understanding
of the regulation of microRNA biogenesis and activity will undoubtedly provide important insights
into normal development as well as pathological conditions such as cardiovascular disease and
cancer.
Introduction
microRNAs (miRNAs) have been reported to control
diverse aspects of biology, including developmental tim-
ing, differentiation, proliferation, cell death, and metabo-
lism [1-3]. Because miRNAs exert these functions
primarily through the repression of target genes, the deter-
mination of miRNA targets has been an area of intense
research. Computational and experimental approaches
indicate that a single miRNA may target several dozen or
even hundreds of mRNA [4]. Additionally, more than
60% of human protein coding genes are predicted to con-
tain miRNA binding sites within their 3' untranslated
regions (UTRs) [4,5]. The diversity and number of miR-
NAs suggests that a vast number of normal and patholog-
ical outcomes may be controlled, at least in part, through
miRNA-mediated repression. While some miRNAs are
described as regulating developmental switches mediated
through the repression of a single target, it is increasingly
clear that the majority of miRNAs exert their effects
through the modest reduction of a large number of targets
which altogether give alterations in cellular phenotype
[4,6].
miRNAs select mRNA targets for down-regulation
through the association with a large, multi-protein com-
plex, the RNA Induced Silencing Complex (RISC). This
selection requires the presence of sequences within the
target mRNA which are imperfectly complementary to the
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miRNA sequence; miRNA binding sites commonly occur
within the 3'-untranslated region (UTR) of the mRNA, but
functional miRNA binding sites can also occur with the
5'UTR [7] or coding region [8]. Intriguingly, the presence
of a miR-148 binding site within an alternatively-spliced
exon of DNA (cytosine-5-)-methyltransferase 3 beta
(Dmnt3b) can promote the differential expression of
splice variants [9].
The absence of perfect complementarity between the
miRNA sequence and target sites complicates the identifi-
cation of miRNA target genes. However, Watson-Crick
base pairing between the target and the 5'-end of miRNAs,
particularly the 'miRNA seed' (comprised of nucleotides
2–7), is an important determinant of functional target
sites [10]. Given that the entire 22 nucleotide (nt)
sequence of many miRNAs is conserved throughout evo-
lution, it is highly likely that the 3'-region of miRNAs also
plays a critical role in the determination of miRNA targets
[10,11]. Although the identification of miRNA targets has
been enabled by computational approaches, it remains
unclear what determines the degree of repression of a
given miRNA-target mRNA pair.
The precise mechanism of miRNA-mediated gene regula-
tion has been a subject of intense research [12]; miRNAs
have been reported to repress the translation of target
mRNA by blocking translation initiation and/or elonga-
tion [13-16]. Alternatively, targets of miRNA may be
sequestered away from the translation machinery and
transferred to processing-bodies (p-bodies), where
mRNAs are known to be degraded [17]. The precise mech-
anism of miRNA-mediated translational repression varies
depending on the specific system of study, and is reviewed
in detail elsewhere [12]. Although early work with let-7
suggested that miRNAs act primarily at the level of trans-
lation without altering mRNA levels [13], recent genome-
wide profiling experiments indicate that most highly
repressed miRNA targets exhibit some degree of mRNA
degradation [6]. miRNA interaction may promote the
destabilization of target mRNAs through the recruitment
of decapping and deadenylation complexes [18,19]. Alter-
native mechanisms of mRNA repression may be utilized
depending on the cellular context, RNA secondary struc-
ture, or effector proteins associated with a specific
miRNA:mRNA pair [20]. For example, transcription of a
miRNA from different promoters altered the specific
mechanism of repression; suggesting that the nuclear his-
tory of a miRNA may influence silencing [21]. The further
clarification of the mechanisms of miRNA-mediated
silencing and the requirements of functional miRNA tar-
get sites is an area of active research and will be important
in understanding the physiological role of miRNA in
diverse areas.
Spatiotemporal regulation of miRNA expression
The founding members of the miRNA family, lin-4 and
let-7, were originally identified in C. elegans and described
as small temporal RNAs (stRNA) due to their specific pat-
tern of expression during development [22,23]. Amaz-
ingly, the temporal regulation of let-7 miRNA was
conserved through humans, suggesting that miRNAs
could be expressed in defined spatiotemporal patterns
[24]. This observation has been further extended as the
expression profiles of more miRNAs have been deter-
mined. miRNA profiling in mouse and human adult
organs indicated ~50% of miRNAs are expressed in a tis-
sue-specific manner [25,26]. For example, cloning of
small RNAs from different mouse tissues identified miR-
1, miR-122a, and miR-124 as highly enriched in the heart,
liver, and brain, respectively [27]. In situ hybridization of
zebrafish embryos identified a large percentage of tissue-
specifically expressed miRNAs which are also temporally
regulated during development [28]. Furthermore,
increased expression of tissue-specific miRNAs (ie: miR-
124 in neurons, let-7 in differentiated cells) represses pro-
genitor cell-specific mRNA to increase the fidelity of cell
fate transition during differentiation [29,30].
Given the importance of miRNAs in development, it is not
surprising that deregulation of miRNA expression is
implicated in a variety of human diseases, including can-
cer and heart failure. Many miRNAs are located at sites of
genomic instability, including duplications and fragile
sites [31]. Global miRNA expression is frequently reduced
in tumor samples relative to normal tissues, suggesting a
role for miRNA in maintaining differentiated cell pheno-
types. Indeed, let-7 expression is often dramatically
reduced in lung cancer and exogenous expression of let-7
can dramatically inhibit tumor growth in vivo [32]. Con-
versely, a subset of miRNAs, including miR-21 and miR-
155, have been identified as highly expressed in a variety
of tumors and may serve to promote tumor growth
through the inhibition of pro-apoptotic pathways.
miRNA expression profiling serves as a better predictor of
tumor origin and prognosis than conventional gene
arrays, further emphasizing the importance of miRNAs in
oncogenesis [33]. For example, a recent miRNA profiling
study of pancreatic tissues indicates that the expression of
as few as 25 miRNAs could distinguish among pancreatic
adenocarcinoma, chronic pancreatitis, and normal pan-
creatic tissue [34,35]. Furthermore, the pattern of miRNA
expression serves as a highly reliable tool to predict thera-
peutic outcomes in leukemia and colon cancer [36,37].
Understanding the mechanisms that control both normal
and deregulated miRNA expression may lead to new ave-
nues for treatment of a variety of disorders.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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Overview of miRNA biogenesis
The evolutionarily-conserved mechanism which gives rise
to mature miRNA involves two ordered endonucleolytic
cleavages by the RNase III enzymes Drosha and Dicer (Fig.
1) [38]. Following transcription by RNA polymerase II
(RNA pol II), Drosha processes the primary miRNA tran-
script (pri-miRNA) into a ~60–100 nt hairpin structure
termed the precursor-miRNA (pre-miRNA) [39-42].
Through the interaction with exportin-5 and Ran-GTP, the
pre-miRNA is transported into the cytoplasm, where it
undergoes a second round of processing catalyzed by
Dicer (Fig. 1) [43,44]. This cleavage event gives rise to a
double-stranded ~22 nt product comprised of the mature
miRNA guide strand and the miRNA* passenger strand.
The mature miRNA is then loaded into the RISC while the
passenger strand is degraded (Fig. 1) [45]. Although major
progress has been made in understanding the basic mech-
anism of miRNA biogenesis, less is known about the spe-
cific mechanisms that regulate miRNA expression. As
discussed below, each step of the general biogenesis path-
way has been found to be differentially regulated to allow
exquisite control of miRNA expression. Recent studies
have revealed that all miRNAs are not created equally and
different mechanisms allow for the specific control of
individual miRNAs.
Genomic organization and transcription of 
miRNA genes
miRNAs are encoded in diverse regions of the genome
including both protein coding and non-coding transcrip-
tion units. Approximately 50% of miRNAs are derived
from non-coding RNA transcripts, while an additional
~40% are located within the introns of protein coding
genes [46,47]. The majority of miRNAs are transcribed by
RNA polymerase (RNA pol) II and bear a 7-methyl guan-
ylate cap at the 5' end and poly (A) tail at the 3' end, sim-
ilar to mRNAs (Fig. 1) [39,48]. RNA pol III has also been
demonstrated to generate the transcripts of a subset of
miRNAs [49,50]. Co-regulation of mRNA and miRNA
expression can be achieved by embedding the miRNA
sequence within the intron of protein coding genes, or
occasionally within the 3'UTR of a mRNA [47]. Further-
more, some miRNAs present in the 3' flanking regions of
coding genes may be generated by read-through transcrip-
tion [51].
Drosha cleavage of intronic pri-miRNA precedes splicing,
and the insertion of a miRNA hairpin into an intron does
not alter host gene splicing or stability, indicating that a
single transcript could give rise to both miRNA and mRNA
[48,51,52]. Additionally, in some cases, the presence of a
miRNA within an intron may enhance processing of the
miRNA by extending the time of pri-miRNA association
with chromatin [53]. An important role for intronic miR-
NAs is highlighted by the muscle specific miRNAs (or
Biogenesis of miRNAs and assembly into RISC complex Figure 1
Biogenesis of miRNAs and assembly into RISC com-
plex. RNA pol II generates capped and polyadenylated pri-
miRNAs which are processed by Drosha in the nucleus to 
generate pre-miRNAs. After translocation into the cyto-
plasm by exportin 5, pre-miRNAs are processed by Dicer to 
form the mature miRNA/miRNA* duplex. Following process-
ing, miRNAs are assembled into the RISC complex. Only one 
strand of the duplex is stably associated with the RISC com-
plex. The mature miRNA directs repression of mRNA con-
taining partially complementary miRNA binding sites within 
the 3'UTR.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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myo-miRs) miR-208, -208b and -499, which are encoded
within the introns of myosin heavy chain (MHC) genes
(Fig. 2A) [54]. MHC genes are specifically expressed in car-
diac muscle and therefore drive the tissue-specific expres-
sion of myo-miRs. Furthermore, the expression of α-MHC
and  β-MHC is reciprocally regulated during cardiac
remodeling following injury (Fig. 2A). In vivo evidence
suggests that miR-208 encoded within the α-MHC gene
utilizes diverse signaling mechanisms to control expres-
sion of the miR-208b host gene, β-MHC [55].
The presence of miRNA within an intron does not neces-
sitate co-regulation of the miRNA with the host gene.
Microarray analysis of miRNA expression of 175 miRNAs
in 24 human organs found just 16 of 34 intronic miRNAs
that were strongly co-expressed with the host gene [56].
The difference in host gene and mature miRNA expression
could occur through differential miRNA processing or
through alternative promoter usage. Indeed, nucleosome
mapping studies and RNA pol II chromatin immunopre-
cipitation studies indicate that 25–33% of intronic miR-
NAs are transcribed from independent promoters [50,57].
Many miRNAs are encoded in the genome as clusters
which can range from 2 to 19 miRNA hairpins encoded in
tandem in close proximity. Detection of polycistronic
transcripts containing multiple miRNAs by Northern blot
suggests that clustered miRNAs can derive from a single
miRNA regulatory circuits Figure 2
miRNA regulatory circuits. A. The cardiac specific miR-208 family is encoded within the introns of myosin heavy chain 
(MHC) genes. miR-208 targets THARP1, which then down regulates the expression of β-MHC gene. B. Expression of miR-124 
is negatively regulated by the binding of the RE1 silencing transcription (REST) factor to the promoter in non-neuronal cells. C. 
Examples of feed-back regulation of microRNA transcription through the repression of transcription factors.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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transcript [56]. However, it is clear that clustered miRNAs
are not necessarily co-regulated [25,58]. While some clus-
tered miRNAs can arise from independent transcripts, as
in the case of miR-433 and miR-127 [59], differential
post-transcriptional processing of clustered miRNAs has
also been observed, as in the case of miR-18a [60]. Addi-
tionally, in some instances, a single miRNA locus can give
rise to two miRNAs with distinct seed sequences through
bidirectional transcription [61,62].
Regulation of miRNA expression: Transcription
RNA pol II mediated transcription provides a major con-
trol point for the biosynthesis of miRNAs. A recent large
scale mapping of 175 human miRNA promoters through
nucleosome positioning and chromatin immunoprecipi-
tation-on-genomic DNA microarray chip (or ChIP-on-
chip) analysis suggests that the promoter structure of
miRNA genes, including the relative frequencies of CpG
islands, TATA box, TFIIB recognition, initiator elements,
and histone modifications, is indistinguishable between
the promoters of miRNA and mRNA [50,57]. Further-
more, DNA binding factors that regulate miRNA tran-
scription largely overlap with those that control protein
coding genes.
c-Myc: a critical regulator of miRNA transcription
The proto-oncogene c-Myc is a helix-loop-helix leucine
zipper transcription factor which regulates ~10 to 15% of
human genes to control cell growth and apoptosis [63].
Deregulation of c-Myc is a hallmark of many cancers and
is associated with both activation and repression of tran-
scription of protein coding genes [64]. It is now clear that
c-Myc also modulates transcription of miRNA genes
[65,66]. c-Myc binds to E-boxes in the promoter and acti-
vates transcription of the miR-17-92 cluster [65]. Consist-
ent with the prominence of c-Myc activation in tumors,
miR-17-92 is often highly expressed in tumors. The miR-
17-92 cluster contains 6 miRNAs, including miR-17-5p
and miR-20, which are known to repress the cell cycle reg-
ulator E2F1 [65]. Interestingly, c-Myc also promotes E2F1
transcription; suggesting that c-Myc is able to fine tune cell
cycle progression via the regulation of both miRNA and
mRNA expression (Fig. 2C) [67]. In addition to activating
transcription, c-Myc also decreases the expression of sev-
eral tumor suppressor miRNA genes, including the miR-
15a, -29, -34 and let-7 families [66]. Exogenous expres-
sion of c-Myc-repressed miRNAs in lymphoma cells
reduced cell growth, indicating that down regulation of a
subset of miRNAs is an important mechanism of c-Myc-
mediated tumorigenesis [66]. ChIP analysis reveals that
this repression is mediated, at least in part, through direct
binding of c-Myc to miRNA promoters [66]. Interestingly,
c-Myc has also been shown to increase transcription of
Lin-28B which in turn mediates the post-transcriptional
repression of let-7 family members (Fig. 3 and discussion
below) [68]. Consistent with the repression of let-7 by c-
Myc, increased expression of c-Myc in Burkitt lymphoma
cells is associated with decreased let-7 expression [69]. c-
myc is also targeted by let-7, suggesting a double negative
feed-back loop in which c-Myc represses let-7 transcrip-
tion and let-7 in turn represses c-Myc (Fig. 3) [69].
Together these studies provide just one example of the
dynamically regulated transcriptional control of miRNAs
and are illustrative of the biological outcomes which are
mediated by altered transcription of miRNA genes. c-Myc
is not alone in this arena: the tumor suppressor p53 acti-
vates transcription of the miR-34 family, which in turn
promotes cell cycle arrest and apoptosis [70,71].
miRNA transcription networks
The tissue-specific expression of protein coding genes is
controlled by complex transcription factor networks
which orchestrate the differentiation and maintenance of
cell fate in specialized tissues. Consistently, the transcrip-
tion of tissue-specific miRNAs is often modulated by the
same master regulatory factors which regulate mRNA. For
example, skeletal and cardiac muscle differentiation is
characterized by the transcriptional activation of muscle
specific genes through the cooperation of serum response
factor (SRF) and myocyte enhancer factor 2 (MEF2) with
muscle-specific basic-helix-loop-helix transcription fac-
Intricate network of regulation of let-7 expression and activ- ity by different proteins Figure 3
Intricate network of regulation of let-7 expression 
and activity by different proteins. Multiple mechanisms 
give rise to an intricate feed-back loop which controls the 
expression of let-7 and Lin-28. Lin28, which is highly 
expressed in undifferentiated, embryonic stem cells, selec-
tively blocks the processing of let-7 miRNAs through multi-
ple mechanisms including Drosha blockade, Dicer blockade, 
and 3'-uridylation of pre-let-7. The highly regulated expres-
sion of let-7 is critical for the control of cellular differentia-
tion and proliferation.
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tors, including Myf-5, MyoD, and Myogenin [72]. SRF and
MEF2 have recently been described to also promote the
transcription of several myocyte-specific miRNAs, includ-
ing miR-1, -133, -206, and -208 (Fig. 2C) [54]. Similar to
myogenesis, the regulation of haematopoetic cell differen-
tiation is controlled by combinations of lineage-specific
transcription factors. miR-223 is highly expressed in the
myeloid cell lineage and is activated by the myeloid tran-
scription factors, C/EBP and PU.1 [73]. The coordinated
expression of tissue specific miRNAs with mRNAs may
serve to enforce cell fate switching during development.
Negative regulation of miRNA transcription has also
evolved to prevent misexpression of cell type-specific
miRNAs. For example, expression of miR-124, which is
abundant in brain, is negatively regulated by the binding
of the RE1 silencing transcription (REST) factor to the pro-
moter (Fig. 2B) [74]. REST and its cofactor Small C-termi-
nal domain phosphatase 1 (SCP1) are highly expressed in
neuronal precursors and non-neuronal genes. The REST
complex silences transcription of neuronal genes through
the recruitment of histone deacetylases (HDACs) and the
methyl CpG binding protein MeCP2 [75]. Therefore, the
REST complex prevents the misexpression of neuronal
genes, including miR-124, outside of the nervous system.
The interplay between the REST complex and miR-124
sets up a feedback loop which stabilizes and enforces the
expression of neuronal vs. non-neuronal genes (Fig. 2B)
[74,76]. Given that exogenous expression of miR-124 in
HeLa cells down-regulates hundreds of non-neuronal tar-
gets, the tight control of miR-124 expression is critical for
the diversification of neuronal from non-neuronal cells
[77].
Bioinformatic analyses indicate that miRNAs may have a
general propensity to regulate transcription factors [78].
Interestingly, an emerging theme in tissue-specific miRNA
regulation is that miRNAs are often involved in complex
regulatory networks with the transcription factors that
drive their expression. Autoregulation of miRNA expres-
sion is found when the transcription factor which regu-
lates miRNA expression is targeted by the miRNA itself.
Examples of this type of regulation include Runx1-miR-
27a in megakaryopoiesis [79], Pitx3-miR-133b in mid-
brain dopaminergic neurons [80] and c-Myb-miR-15a in
hematopoiesis (Fig. 2C) [81]. This type of regulation
allows tight control of miRNA and transcription factor
levels. Feed-forward circuits have also been identified. In
the heart, HDAC4 represses the MEF2/MyoD regulated
transcription of myogenic factors. miR-1 is induced by
MEF2/MyoD and silences HDAC4, the resulting decrease
in HDAC4 allows increased activity of MEF2/MyoD and
thus mediates further expression of miR-1 loci (Fig. 2C)
[82]. It is speculated that feed-forward circuits ensure sus-
tained, robust expression of miRNAs and may play a role
in promoting tissue-specific miRNA expression.
In addition to the stable changes in miRNA transcription
modulated by developmental programs, miRNA can also
be rapidly, and in some cases, transiently induced by
growth factor signaling. Vascular smooth muscle cells
(VSMC) retain the unique ability to undergo phenotypic
switching between a differentiated 'contractile' state and a
de-differentiated 'synthetic' state. This process is critically
important for the repair of vessels following injury, but
deregulation of phenotype switching contributes to vascu-
lar disorders, including hypertension, balloon-angi-
oplasty-induced restenosis, and atherosclerosis. A critical
player in the dedifferentiation of VSMC are the platelet
derived growth factors (PDGFs), which promote reduced
contractile gene expression, increased migration and
increased proliferation of smooth muscle cells [83]. PDGF
signaling results in a rapid, transcriptional induction of
miR-221 which is required for multiple facets of the syn-
thetic VSM response [58]. Interestingly, miR-222 which is
a part of the miR-221 gene cluster, is not co-regulated by
PDGF [58]. Induction of miR-221 promotes increased
proliferation and migration as well as decreased contrac-
tile gene expression through distinct targets, indicating
that a single miRNA can extrapolate an extracellular input
to mediate multiple biological outcomes [58]. Other
examples of growth factor-mediated activation of miRNA
genes include miR-132 which is induced in neurons by
brain derived neurotrophic factor (BDNF) and miR-192
which is induced in the diabetic kidney by transforming
growth factor-β (TGF-β) [84,85]. Rapid induction of miR-
NAs in response to growth factors may serve to promote a
switch in gene expression and are likely to be important
for cellular responses upon cytokine stimulation.
Epigenetic control of miRNAs
As the majority of miRNA genes are transcribed by the
same RNA polymerase as protein coding genes, the mech-
anisms of epigenetic control known for protein coding
genes are likely to also apply to miRNA loci. Aberrant
DNA methylation of tumor suppressor genes is a com-
mon occurrence in cancer; accordingly, several miRNA
loci including miR-9-1, -193a, -137, -342, -203 and -34b/
c, are found to be hypermethylated in multiple human
cancers [86,87]. Conversely, the let-7a-3 locus was found
to be hypomethylated in lung adenocarcinoma and ele-
vated expression of this locus resulted in enhanced onco-
genic gene transcription [88]. miRNA promoters are also
regulated by histone modifications during development
and pathogenesis. Histone deacetylase (HDAC) inhibitors
have been reported to up-regulate a subset of miRNAs,
including miR-1 in cancer cells [89,90]. Alternatively, in
the breast cancer cell line SKBr3, 32 mature miRNAs were
significantly downregulated by treatment with HDAC
inhibitors [91]. Interestingly, miR-27a was strongly
repressed by HDAC inhibitor and was found to target
genes previously shown to be up-regulated by HDACCell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
Page 7 of 22
(page number not for citation purposes)
treatment [91]. These findings suggest that changes in
gene expression previously linked to HDAC activity may
be partly due to altered miRNA expression. In normal
development, acetylation of lysine 56 of histone H3
marks many genes responsible for embryonic stem cell
pluripotency, including nanog, sox2, oct4 as well as 13
miRNAs highly expressed In stem cells [92]. In addition to
transient regulation mediated by acetylation and methyl-
ation, miRNA are also subject to stable epigenetic control
through genomic imprinting. Two well-characterized
imprinted regions, H19 and the Dlk1-Gtl2 domains have
recently been found to contain miRNA clusters [93,94].
Given that imprinted regions are often associated with
human genetic disorders and differential imprinting is
required for normal development, these miRNAs may
have a yet unidentified regulatory role during develop-
ment [95]. As in the case of protein coding genes, epige-
netic modifications of miRNA loci provides an additional
layer of transcriptional control in normal development
and disease.
The core Drosha processing machinery
Analysis of mature and primary transcripts of miRNAs in
68 tumor and 22 normal samples indicated that the corre-
lation between the primary transcript and mature miRNA
was disrupted in the tumor samples, perhaps suggesting
global alterations in miRNA processing [96]. Further-
more, the levels of mature miRNA are generally decreased
in tumors in comparison with normal tissues [33]. Exper-
imental knockdown of miRNA processing factors, such as
DiGeorge syndrome critical region 8 (DGCR8), Drosha,
or Dicer in mouse lung adenocarcinoma cells dramati-
cally elevates properties of tumorigenesis, including pro-
liferation, soft agar colony formation, and in vivo tumor
burden [97]. Together, these results indicate that dis-
rupted miRNA biogenesis can alter the delicate balance of
normal cellular physiology.
Following transcription, the primary miRNA undergoes
two cleavage steps to generate the mature miRNA (Fig. 1).
The first cleavage is catalyzed in the nucleus by the RNase
III enzyme Drosha [40,42,98]. Pri-miRNAs generated by
the transcriptional machinery are generally several thou-
sands of nucleotides long and contain a distinctive stem
loop structure. Drosha cleaves at the base of the stem to
generate a ~60–100 nt hairpin RNA with a characteristic 2
nt 3' overhang (Fig. 1) [40]. The Drosha processing of a
subset of miRNAs can be closely coupled with pri-miRNA
transcription. Co-transcriptional Drosha processing
occurs for independently transcribed (intergenic) miRNAs
as well as those embedded within the introns of host
genes [51]. Nuclear fractionation studies indicate that
some pri-miRNAs may remain associated with chromatin
following transcription [51,53]. Furthermore, mutation
of the pri-miRNA cleavage and polyadenylation signal
enhances association of the pri-miRNA with chromatin
and increases the efficiency of Drosha cleavage [53]. It is
well established that many pre-mRNA processing activi-
ties, such as 5' capping, splicing, and 3' poly(A) adenyla-
tion, occur while pre-mRNAs are undergoing
transcription. Therefore it is perhaps not too surprising
that Drosha cleavage of some pri-miRNAs also occurs co-
transcriptionally. The association of Drosha with nascent
transcripts may enable further control of processing
though the recruitment of additional factors or altered
rates of the elongation step of transcription mediated by
RNA pol II.
The precise position and orientation of Drosha cleavage is
critically important for the generation of mature miRNA
because the second cleavage step occurs at a defined dis-
tance from the free end generated by Drosha. Therefore,
Drosha cleavage determines the identity of both the 5' and
3' nt of the mature miRNA. The slightest error in Drosha
cleavage could alter not only the seed sequence, but could
also invert the relative stability of the two strands, result-
ing in the incorporation of the improper miRNA strand
into the RISC complex. Recombinant Drosha can pro-
mote RNA cleavage in vitro, however, the position of cleav-
age is imprecise [41]. In vivo, Drosha is present in a large
protein complex (minimally 650 kDa in human cells) and
the association of Drosha with co-factors present within
this complex promotes the fidelity and activity of Drosha
cleavage. In particular, DGCR8 is required for Drosha-
mediated cleavage of pri-miRNAs [99,100]. The pri-
miRNA is composed of a ~33 nt stem connected by a ter-
minal loop and flanked by single-stranded segments.
DGCR8 is thought to recognize the region between the
single-stranded RNA and the stem in order to direct Dro-
sha cleavage one helical (~11 bp) turn away from this
junction [101]. Some miRNAs contain large terminal
loops that may be structurally similar to the single-
stranded flanking RNA [98]. In vitro, the recognition of a
terminal loop by the DGCR8-Drosha complex could
result in cleavage at a site ~11 bp away from the loop-stem
junction [101]. This placement of Drosha results in an
abortive cleavage within the mature miRNA sequence and
leads to the reduction of mature miRNA expression. To
prevent abortive processing in vivo, the correct positioning
of Drosha on the hairpin structure may be facilitated by
additional co-factors. Furthermore, while the cropping of
many miRNAs can be mediated in vitro by purified
DGCR8 and Drosha, nuclear run-on and in vitro process-
ing assays indicate that pri- to pre- cleavage of some
miRNA is relatively slow and inefficient [51]. Therefore,
the efficient processing of some miRNA by the Drosha/
DGCR8 complex may require the involvement of acces-
sory factors.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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Drosha interacts with a wide variety of proteins in addi-
tion to DGCR8; mass-spec analysis indicates that flag-
tagged Drosha expressed in HEK293 cells is associated
with at least 20 distinct polypeptides [41]. These associ-
ated proteins may be required for the Drosha processing
of specific miRNA sequences/structures or involved in the
differential regulation of processing through 1) preven-
tion of abortive processing, 2) alteration of the miRNA
hairpin structure, 3) enhanced recruitment or positioning
of Drosha on the hairpin, or 4) increased RNA cleavage
activity. As discussed below, the biogenesis of specific
groups of miRNAs are altered by Drosha binding partners
which interact in a sequence- or structure-specific manner
with pri-miRNAs. These mechanisms provide an impor-
tant method for the control of miRNA expression during
development, and deregulation of these processes is likely
to contribute to multiple pathological outcomes.
Modulation of Drosha activity
The DEAD-box RNA helicases p68/p72
The DEAD-box RNA helicases p68 (DDX5) and p72
(DDX17) were identified as components of the large Dro-
sha processing complex by immunoprecipitation-mass
spectrometry analysis and subsequently shown to also
associate with DGCR8 [41,102]. Knockout of either p68
or p72 in mice is lethal (E11.5 or P2, respectively) and
double knockout animals show earlier lethality without
obvious specific degeneration of organogenesis [103].
Analysis of mature miRNA levels by microarray indicated
reduced steady state levels of ~35% (94 out of 266 sur-
veyed) miRNA in p72 null MEFs vs. control. Most of the
miRNAs which were reduced by p72 knockout were simi-
larly reduced by p68 knockout, and combined reduction
of p68 and p72 did not further reduce mature miRNA lev-
els; suggesting that the two proteins are largely redundant
or function as a heterodimer. Interestingly, while the level
of pre-miRNA was also reduced in p72 or p68 knockout
cells, the level of pri-miRNA was unchanged. Further-
more, in vitro processing assays showed attenuation of
Drosha processing from extracts depleted of p68/p72. In
vivo  RNA-immunoprecipitation (RNA-IP) studies indi-
cated reduced Drosha binding to pri-miR-199a in the
absence of p68/p72. Together, these results strongly sup-
port a role for p68/p72 in promoting the Drosha process-
ing of a sub-set of miRNAs [103]. The precise mechanism
of p68/p72-mediated processing is unclear, but may
involve rearrangement of the RNA hairpin which results
in enhanced Drosha recruitment or stability. Alterna-
tively, as p68/p72 are known to interact with a variety of
proteins, including RNA processing enzymes and tran-
scription factors, they may serve as a scaffold for the
recruitment of multiple protein factors to the Drosha
microprocessor [104,105].
The Smads
The role of p68/p72 in miRNA processing is further sup-
ported by the positive regulation of Drosha processing
mediated by the p68-interacting Smad proteins. The
Smads are the signal transducers of the Transforming
Growth Factor-β (TGF-β) family signaling cascade. In the
canonical pathway, ligand binding to the type I and type
II TGF-β receptors promotes the nuclear accumulation of
receptor-Smads (R-Smads) in association with the com-
mon-Smad (co-Smad), Smad4 (Fig. 4). The complex of R-
Smad and co-Smad bind to sequence elements within the
promoter of target genes to positively or negatively regu-
late gene transcription. TGF-β and its family member,
Bone Morphogenetic Protein 4 (BMP4) are particularly
important for the differentiation of VSMCs. Treatment
with either BMP4 or TGF-β increases expression of con-
tractile smooth muscle genes; this process is due, at least
in part, to the miR-21-mediated repression of pro-
grammed cell death protein-4 (PDCD4). miR-21 is rap-
idly induced by BMP4 and TGF-β in VSMC which results
in a subsequent decrease in PDCD4 and increased smooth
muscle gene expression [106]. Interestingly, although
knockdown of the R-Smads prevented upregulation of
mature and pre-miR-21 in response to BMP4, no altera-
tion in pri-miR-21 transcription could be detected. Fur-
thermore, BMP4 could increase the expression of pre- and
mature miR-21 driven by a heterologous promoter, sug-
gesting that miR-21 is post-transcriptionally regulated at
the Drosha processing step by the Smads. The identifica-
tion of R-Smads as binding partners of p68 by yeast-two-
hybrid suggested that R-Smads could be associated with
the Drosha complex [107]. Consistently, co-immunopre-
cipitation and RNA-ChIP studies indicate Smad is present
in a complex with Drosha and p68 on the pri-miR-21
hairpin following BMP4 or TGF-β stimulation (Fig. 4)
[106]. An increase in Drosha binding to pri-miR-21 was
also observed following ligand treatment, suggesting that
Smads may promote the association of Drosha with
miRNA hairpins. These results indicate that in addition to
transcriptional regulation mediated by the Smads, TGF-β
can regulate gene expression through miRNA processing
(Fig. 4). A distinguishing feature of the two pathways is
the requirement for the co-Smad4. While Smad4 is
required for transcriptional responses to TGF-β, the asso-
ciation of R-Smads with the Drosha processing machinery
does not require Smad4. Knockdown of Smad4 in VSMC
did not affect induction of miR-21; furthermore, miR-21
is strongly induced by TGF-β in the Smad4-null MDA-MB-
468 breast cancer cell line [106]. Several other miRNAs are
post-transcriptionally induced by BMP and TGF-β, sug-
gesting that rapid modulation of miRNA levels may play
an important role in cellular response to cytokine signal-
ing (B. Davis and A. Hata, unpublished observation)
[106]. Intriguingly, knockdown of Smad nuclear interact-
ing protein 1 (SNIP1) in HeLa cells reduces the expressionCell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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of several mature miRNAs, including miR-21 [108]. Fur-
thermore, SNIP1 is found in complex with RNA process-
ing enzymes [109] as well as Drosha [108]. The
Arabidopsis homologue of SNIP1, DAWDLE, is required
for efficient pri- to pre-miRNA processing and is thought
to promote the access or recognition of pri-miRNA by
DCL1 [108]. These results suggest that Smads may be
present in large, multi-protein complexes which regulate
mature miRNA levels through alteration of miRNA
processing in a context dependent manner.
p53
The tumor suppressor protein p53 was recently identified
to modulate miRNA processing through association with
p68 and Drosha, similar to the Smads. Under conditions
of DNA damage, several miRNAs, including miR-143 and
miR-16, are post-transcriptionally up-regulated [110].
p53 is required for this process as p53-null HCT116 cells
do not increase miRNA in response to DNA damage. Co-
immunoprecipitation studies indicate that p53 is present
in a complex with both Drosha and p68, and addition of
p53 to in vitro processing assays could enhance Drosha
processing [110]. Interestingly, several p53 mutants that
have been previously linked to oncogenic progression
suppressed miRNA expression [110]. These results indi-
cate that the association of p68/Drosha with accessory fac-
tors, such as p53 or Smads, may be particularly important
for the rapid induction of miRNAs in response to extracel-
lular stimuli. It intriguing to speculate that other p68-
interacting proteins, such as estrogen receptors, MyoD,
Regulation of miRNA maturation by the TGF-β superfamily signaling Figure 4
Regulation of miRNA maturation by the TGF-β superfamily signaling. TGF-β and BMP signaling stimulates the pro-
duction of pre-miR-21 by promoting the Drosha-mediated processing by controlling nuclear localization of R-Smad proteins. 
Thus, Smads regulate gene expression in two distinct manners; (i) transcriptional regulation by DNA binding and (ii) regulation 
of miRNA maturation by associating with the Drosha/DGCR8 complex.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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and Runx2 [111-113], might also have a role in the regu-
lation of miRNA processing.
The heterogeneous nuclear ribonucleoprotein A1 (hnRNP 
A1)
An additional example of miRNA specific processing reg-
ulation is mediated by hnRNP A1 which is required for
the processing of a member of the miR-17-92 cluster,
miR-18a. Addition of hnRNP A1 to in vitro processing
assays dramatically increases the conversion of pri-miR-
18a to pre-miR-18a. Conversely, depletion of hnRNP A1
lowers pre-miR-18a levels, but does not alter the expres-
sion of the other 5 clustered miRNAs [60]. Further studies
indicate that direct binding of hnRNP A1 to the loop
region of miRNA hairpins causes the structural rearrange-
ment of the hairpin to generate a more favorable Drosha
cleavage site. The addition of 2'O-methyl oligonucle-
otides ('looptomiRs') complementary to the loop region
inhibits hnRNP A1 binding and prevents hnRNP A1-
mediated Drosha processing. The loop region of miR-18a
is well conserved throughout evolution, emphasizing the
importance of the hnRNP A1-loop interaction for the
processing of miRNA. Interestingly, approximately 14%
of human miRNAs contain highly conserved loop regions,
suggesting that processing regulation by hnRNPs may
extend well beyond miR-18a. Consistently, the processing
of two other miRNAs bearing conserved loops, miR-101
and let-7a-1 is also prevented by complementary loop-
tomiRs (Fig. 3) [114]. The human genome encodes at
least 19 hnRNPs, many of which have distinct RNA bind-
ing properties and tissue distribution [115,116]. Indeed,
miR-101 and let-7a-1 were found to associate with hnRNP
L and hnRNP I, respectively [114]. Although the func-
tional requirement for the association of other hnRNPs is
unknown, it suggests that the large family of hnRNPs
could serve as accessory factors in the regulated processing
of a variety of miRNAs. The differential expression of
hnRNP proteins as well as their sub-cellular localization
may serve to regulate miRNAs in a tissue or context-
dependent manner. For example, phosphorylation of
hnRNP A1 by p38 MAPK has been reported to promote
the cytoplasmic localization of hnRNP A1 [117,118].
These results suggest that, similarly to smads, hnRNP A1
may control miRNA processing in response to extracellu-
lar stimuli.
The KH-type splicing regulatory protein (KSRP)
The importance of the loop region in the regulation of
miRNA processing is further supported by recent studies
which indicate KSRP directly interacts with G-rich regions
present within the loop of a sub-set of miRNAs to pro-
mote both Drosha and Dicer mediated miRNA processing
[119]. Transient knockdown of KSRP in HeLa cells
strongly reduced the expression of a group of mature miR-
NAs, including let-7a, and miR-206 (Fig. 3). Knockdown
of KSRP altered cellular responses mediated by these miR-
NAs, including proliferation and skeletal muscle differen-
tiation. KSRP was found to be present in both the Drosha
and Dicer complexes, and knockdown of KSRP reduced
the processing activity of Drosha and Dicer [119]. The
interaction of KSRP with sequential miRNA processing
steps may serve to promote the synergistic activation of
processing for a subset of miRNA. Alternatively, KSRP
association with either the Drosha or Dicer complexes
may be sufficient to alter the miRNA processing in
response to cellular stimuli. For example, lipopolysaccha-
ride (LPS) treatment of macrophages dramatically
increases mature miR-155, without significantly altering
expression of the primary transcript. Mobility shift assays
indicate KSRP interacts with pri-miR-155, and knock-
down of KSRP prevents LPS-mediated increase of miR-
155 [120]. Together these results suggest a role for KSRP
in promoting the post-transcriptional regulation of miR-
155 in response to LPS. Although the mechanism of this
regulation is unknown, it is intriguing to speculate that
the sub-cellular localization or modification of KSRP
could be regulated by LPS. Indeed, phosphorylation of
KSRP Serine 193 by Akt promotes nuclear accumulation
of KSRP through interaction with 14-3-3ζ [121]. An
important future challenge is the determination of the sig-
naling pathways which modulate the activity of miRNA
processing accessory factors such as KSRP and hnRNPs.
Lin-28
In addition to the positive regulation of miRNA process-
ing discussed above, negative regulation of the Drosha
processing of some miRNAs has also been reported. The
let-7 family of miRNAs is often present as multiple copies
in the genome; the human genome contains 9 mature let-
7 sequences derived from 12 precursors [122]. While most
let-7 primary transcripts are highly expressed throughout
development, the mature let-7 is detectable only in highly
differentiated cells, suggesting a mechanism of post-tran-
scriptional regulation [122]. Analysis of the primary
miRNA sequences of the human let-7 family as well as let-
7 from divergent species indicated the presence of con-
served nucleotide sequences present in the hairpin loop,
suggesting a possible regulatory role for this region
[123,124]. While pri-let-7 is processed efficiently in vitro
using cell extracts derived from differentiated cells,
processing is reduced in extracts derived from undifferen-
tiated cells. The addition of short oligonucleotides corre-
sponding to the loop region to in vitro processing
reactions prevents inhibition of Drosha processing in cell
extracts, presumably by competing for inhibitor binding
[123]. Affinity purification and mass-spec identified Lin-
28 as the let-7 interacting protein responsible for process-
ing inhibition [123,125]. Furthermore, crosslinking, fol-
lowed by electrophoretic mobility shift assay (EMSA)
confirmed that the loop region interacts with Lin-28, andCell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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disruption of the Lin-28 binding site within the loop pre-
vented Lin-28-mediated repression of let-7 (Fig. 3)
[123,124]. Further support for the physiological relevance
of let-7 regulation by Lin-28 comes from the observation
that Lin-28 and mature let-7 show reciprocal expression
patterns during development.
The precise mechanism of Lin-28 inhibition of Drosha
processing is unclear. Lin-28 has a strong affinity for let-7,
perhaps suggesting Lin-28 could prevent interaction with
Drosha/DGCR8 by simple competition. Alternatively,
analogous to hnRNP A1 discussed above, Lin-28 interac-
tion with the loop region could rearrange the secondary
structure of the hairpin and, in this case, discourage Dro-
sha processing. It is interesting to note that Lin-28, KSRP,
and hnRNPs all interact with conserved nucleotides
present within the loop of pri-miRNAs. The balanced
interaction of proteins with the miRNA loop may allow
for the fine-tuning of miRNA levels during development
or in response to extracellular cues. For example, although
KSRP interacts strongly with pri-let-7g in differentiated
cells, high levels of Lin28 block KSRP association in undif-
ferentiated p19 cells [119].
The nuclear factor 90/45 (NF90/NF45)
Repression of Drosha processing of let-7 family members
is also mediated by NF90 and NF45 proteins (Fig. 3)
[126]. In vitro and in vivo processing assays indicate that
the NF90/NF45 complex reduces pre-miRNA while
increasing pri-miRNA levels. The NF90/NF45 family of
proteins interacts with small double-stranded RNAs,
including the adenovirus VA RNA [127] consistently, the
NF90/NF45 complex binds pri-miRNAs with high affin-
ity. EMSA analysis suggests that the high affinity associa-
tion of NF90/NF45 complex with pri-miRNA precludes
interaction with DGCR8, thus reducing production of pre-
and mature miRNA [126]. Unlike Lin-28, which specifi-
cally regulates let-7, the NF90/NF45 complex may be
more promiscuous, as the processing of 3 other analyzed
miRNAs is also modulated.
Altered Drosha processing has been described for the
tumor suppressor miR-7 in glioblast4oma [128]. While
the primary miR-7 transcript is expressed at equal levels in
normal and tumor samples, the precursor and mature
miRNA is dramatically reduced in glioblastoma tumor
samples and cell lines. Restoration of miR-7 levels to pri-
mary cell lines reduced the viability and invasiveness by
targeting the EGF Receptor and inhibiting the Akt signal-
ing cascade [128]. As the levels of several other miRNA
were unaffected, the deregulation of processing seems spe-
cific to miR-7. Although the mechanism is unknown,
reduced pre-miR-7 in the tumor could arise from either (i)
increased expression of a processing inhibitor or (ii)
decreased expression of a processing activator. It will be
interesting to determine if miR-7 is regulated by one of the
mechanisms described above, or if yet-unidentified mech-
anisms are responsible for the altered regulation of miR-7
in cancer cells.
Regulation of Drosha/DGCR8 expression
Finally, it has been reported that the total levels of Drosha
and DGCR8 in the cell are tightly controlled and may play
a role in the regulation of miRNA processing. Increased
Drosha expression was identified in late stage cervical can-
cer samples and was associated with poor prognosis of
esophageal cancer patients [129,130]. Interestingly,
despite a 2–7 fold increase in Drosha expression in cervi-
cal cancer samples, only miR-31 was increased, while the
other differentially expressed miRNAs were decreased
[130]. DGCR8 was originally identified as a gene located
within a common chromosomal deletion at ch22q11,
which gives rise to DiGeorge syndrome, including learn-
ing disabilities and heart defects [131]. Mouse models of
this chromosomal deletion exhibit a moderate decrease of
59 mature miRNAs [132]. Given the critical role of Drosha
and DGCR8 in mediating miRNA processing, it is surpris-
ing that relatively minor changes have been found in
miRNA levels upon dramatic alteration of DGCR8/Dro-
sha levels. These findings may be explained, at least in
part, by the recent finding that the total levels of Drosha
and DGCR8 are coupled in an intricate feed-back circuit.
In addition to cleaving pre-miRNA hairpins, the micro-
processor complex can also promote cleavage of hairpin
structures within annotated protein coding genes which
are not further processed by Dicer [133,134]. This type of
cleavage allows Drosha to modulate protein coding gene
expression independent of miRNA production. Indeed,
tiling microarray analysis in drosophila S2 cells following
Drosha depletion indicates that many annotated protein
coding genes, including DGCR8, are targeted for degrada-
tion through this pathway [133]. Therefore, Drosha main-
tains a highly regulated level of DGCR8 through the
microprocessor-mediated cleavage of DGCR8 mRNA.
Additionally, DGCR8 stabilizes Drosha protein levels and
ensures the tight coupling of the core microprocessor pro-
teins. This regulatory loop seems to be highly effective in
vivo as in the DGCR8 heterozygous knockout mouse the
protein levels of DGCR8 are only modestly reduced
despite a 50% decrease in genomic DGCR8 [134]. The
presence of this mechanism suggests that the relative lev-
els of DGCR8 and Drosha must be closely coupled for
accurate miRNA processing. Interestingly, in vitro process-
ing experiments using recombinant proteins indicate that
as little as a 3-fold excess of DGCR8 over Drosha dramat-
ically inhibits processing activity of Drosha [41]. In addi-
tion to alteration of protein levels, the overall activity of
the Drosha/DGCR8 complex may be altered under some
circumstances. Cells grown to high density exhibit
increased pre- and mature miRNA expression withoutCell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
Page 12 of 22
(page number not for citation purposes)
alteration of Drosha or DGCR8 protein level. Further-
more, extracts from high-density cells promoted the more
efficient conversion of pri- to pre-miRNA in in vitro
processing assays [135]. Although the mechanism of this
increased processing is unknown, it is possible that post-
transcriptional modifications or association with acces-
sory factors could alter the activity of Drosha or DGCR8.
For example, the binding of heme to DGCR8 promotes
dimerization of DGCR8 and facilitates pri-miRNA
processing [136].
Drosha-independent miRNA maturation: 
mirtrons
A sub-set of miRNAs which by-pass the Drosha cleavage
step, called 'mirtrons', have been identified. These miR-
NAs are embedded within short introns and the ends of
the pre-miRNA hairpin are determined by the 5' and 3'
splice sites of the intron [137,138]. Following the comple-
tion of splicing, the lariat-debranching enzyme resolves
the branch point to generate a pre-miRNA-like hairpin
that can be exported from the nucleus and further proc-
essed by Dicer. While fly and worm mirtrons generate
hairpins with 2-nt 3' overhangs consistent with the struc-
ture of canonical miRNAs, mammalian mirtrons generally
contain single nucleotide overhangs on both strands
[139]. In general, mirtrons compose only a small percent-
age of genomically-encoded miRNAs and are usually
expressed at a lower level than canonically processed miR-
NAs. While fly, worm, and mammals utilize a similar
mechanism for the generation of miRNAs in the absence
of Drosha activity, the sequences of mirtrons are not evo-
lutionarily conserved. Furthermore, as most mirtrons
have appeared recently on an evolutionary time scale, it is
intriguing to speculate that the conversion of a short
intron into a mirtron may serve as a simple mechanism
for the creation of new regulatory RNAs during evolution
[139].
miRNA export by Exportin-5
The pre-miRNA hairpin is translocated from the nucleus
into the cytoplasm through interaction with exportin-5
(Fig. 1) [140]. Like other nuclear export receptors, expor-
tin-5 cooperates with the small GTPase Ran to mediate
directional transport of proteins. Pre-miRNAs interact
with exportin-5 and the GTP-bound form of Ran in the
nucleus. Following export to the cytoplasm, GTP is hydro-
lyzed and the pre-miRNA is released from exportin-5
[43,141]. Interaction of exportin-5 with RNA is independ-
ent of sequence, but requires a double-stranded region of
at least 16 bp [43,142]. Additionally, a 3' overhang facili-
tates interaction of the pre-miRNA with exportin-5, while
a 5' overhang is inhibitory for the association [142].
Exportin-5 may be particularly well suited to recognize
and export correctly processed miRNA precursors since
Drosha catalyzed cleavage of pri-miRNAs generates a 2-nt
3' overhang.
Knockdown of exportin-5 decreases the levels of cytoplas-
mic miRNA and reduces the ability of both exogenous and
endogenous miRNAs to target a luciferase sensor con-
struct. No accumulation of pre-miRNAs in the nucleus
was observed in the absence of exportin-5, suggesting that
exportin-5 may also serve to stabilize pre-miRNAs [140].
The level of exportin-5 in the cell may be rather limiting
as either overexpression of pre-miRNA or addition of an
alternative exportin-5 substrate, adenovirus non-coding
RNA VA1, blocks nuclear export of radio-labeled pre-
miRNA [141,143]. Furthermore, saturation of the expor-
tin-5 machinery is known to contribute to the toxicity in
liver resulting from high expression of shRNA in mouse
[144]. Conversely, overexpression of exportin-5 could
enhance the activity and total level of exogenous and
endogenous miRNAs [145]. These results are consistent
with nuclear export representing a rate-limiting step in
miRNA biogenesis.
The export of pre-miRNA from the nucleus to the cyto-
plasm may be differentially regulated under certain condi-
tions. For example, the precursor hairpins of miR-105, -
128, and -31 are detected in many cells at relatively high
abundance. However, under some conditions the mature
miRNA is undetectable [26]. Specifically, northern blot
and real time PCR indicate that pre-miR-31 is expressed at
comparable levels in the pancreatic cancer cell line
HS766T and the MCF7 breast cancer cell line. However,
while HS766T cells show high levels of mature miR-31,
no expression is detected in the MCF7 cells. In situ hybrid-
ization for pre-miR-31 showed the expected cytoplasmic
localization in HS766T cells, while in MCF7 cells pre-
miR-31 accumulated in the nucleolus [26]. Together,
these results indicate that the export of pre-miR-31 is reg-
ulated in a cell-type dependent manner; however, the
mechanism of altered miRNA export is unknown. The
precise sequence of the miRNA hairpin alters the effi-
ciency of exportin-5 mediated export in Xenopus oocyte
extracts, suggesting that RNA secondary structure may
lead to differential miRNA export [141]. Alternatively,
because the altered export of miR-31 is observed in a con-
text-dependent manner, an unknown RNA binding factor
may be involved in regulating the export of some miR-
NAs.
Control of Dicer cleavage and RISC loading
Dicer Cleavage and Accessory factors
Following translocation into the cytoplasm, the pre-
miRNA is cleaved near the terminal loop by the RNase
type III protein Dicer to generate a ~22-nt double-
stranded miRNA [146,147] (Fig. 1). Like Drosha, Dicer
generates 2-nt 3' overhangs upon cleavage. Dicer is highlyCell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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conserved throughout evolution and present in nearly all
eukaryotic organisms; the mammalian Dicer is composed
of multiple domains including the DExD/H-box helicase,
DUF283, dsRBD, PAZ and ribonuclease domains [148].
Structural analysis of the Giardia intestinalis Dicer, com-
posed of the PAZ and ribonuclease domains, indicates
that the PAZ domain binds the 3' overhangs at the end of
double-strand RNA to position the RNA for cleavage by
the two catalytic RNase III domains [149]. Interestingly,
replacement of the PAZ domain with a U1A RNA binding
domain resulted in altered end-recognition but main-
tained the length of generated miRNAs [149]. These find-
ings indicate that Dicer serves as a molecular ruler to
cleave miRNA at a specific distance from the ends gener-
ated by Drosha [150]. The Giardia Dicer likely represents
a minimal functional Dicer protein and the additional
domains present in mammalian Dicer may serve to allow
more complex regulation of Dicer activity. Indeed, analy-
sis of the processing ability of Dicer mutants indicates that
the helicase domain may be especially critical for the
processing of hairpins containing thermodynamically
unstable regions [151].
Dicer is associated with the double-stranded RNA binding
proteins TAR RNA binding protein (TRBP) and protein
kinase R-activating protein (PACT) [152,153]. Depletion
of either of these cofactors decreases the steady-state levels
of Dicer protein [153,154]. Furthermore, truncation
mutations of TRBP are found in carcinoma and associated
with both decreased miRNA levels, as well as dramatic
destabilization of Dicer [155]. Dicer protein levels can be
rescued by wild type TRBP, suggesting that the interaction
between Dicer and TRBP is a critical determinant of Dicer
stability [155]. Additionally, the RNA binding protein
fragile × mental retardation protein (FMRP) is associated
with multiple components of the miRNA pathway,
including Dicer [156]. Interestingly, the phosphorylation
of FMRP prevents association with Dicer, but promotes
interaction of FMRP with pre-miRNA [157]. Although the
consequences of FMRP phosphorylation on microRNA
processing are unclear, these results suggest a mechanism
for the regulation of Dicer activity through the phosphor-
ylation of associated proteins.
The RISC Complex
Although recombinant Dicer can catalyze the efficient and
specific cleavage of RNA in vitro, these miRNAs are ineffi-
ciently incorporated into the RISC complex [45]. Further-
more, an exogenous pre-miRNA hairpin is more effective
at promoting the silencing of targets than a duplex RNA,
suggesting that the coupling of Dicer processing and RISC
loading is critical for the proper function of miRNAs [45].
The primary component of the RISC complex, and the
effectors of miRNA-mediated repression are the Argo-
naute (Ago) proteins. The human genome contains eight
Ago-family proteins (Ago1-4 and Piwi1-4) [158].
Although structurally similar to Agos, the Piwi family
members interact with piRNAs and function in germline
maintenance; reviewed in [159]. While all of the Ago pro-
teins have the ability to interact with small RNAs, Ago2 is
the only one with RNA cleavage activity and is thought to
play a prominent role in miRNA-mediated silencing.
In vivo, Ago2 associates with Dicer and TRBP/PACT to
form the RISC Loading Complex (RLC) which allows the
tight coupling of Dicer cleavage to the incorporation of
miRNA into the RISC complex [153]. In vitro reconstituted
RLC composed of recombinant Dicer, TRBP, and Ago2
efficiently catalyzes pre-miRNA cleavage in an ATP-inde-
pendent manner [160,161]. Cleavage by Dicer results in
an unstable double-stranded RNA composed of the active
guide strand (miRNA) and the passenger (miRNA*)
strand (Fig. 1). An important role of the RLC is the
unwinding of the double-stranded miRNA, which is fol-
lowed by incorporation of the guide strand into the
miRNA-containing ribonucleoprotein (miRNP) complex
and degradation of the passenger strand. The mechanism
of strand selection in humans is unclear, however, the
guide strand generally exhibits lower thermodynamic sta-
bility of the 5' end [162]. Deep sequencing of small RNAs
indicates that in most cases, the ratio of miRNA:miRNA*
strand is ~100:1, suggesting a possible mechanism of
active degradation of miRNA* but not miRNA [163].
Although driven by thermodynamic properties, the
assembly of RNA into the RISC complex may be subject to
additional regulation as the ratio of miRNA:miRNA* can
vary dramatically depending on the specific properties of
the miRNA duplex. Furthermore, the ratios of
miRNA:miRNA* are altered in different tissues and devel-
opmental stages [164,165]. These findings suggest that
differential strand selection could represent a yet unappre-
ciated mechanism of miRNA regulation. Recombinant
RLC can mediate strand selection of pre-let-7a, indicating
that this process is intrinsic to the Dicer-TRBP-Ago2 com-
plex, but may be modified by additional factors in a con-
text dependent manner [161].
The presence of a pre-formed Ago2-Dicer complex may be
particularly important for miRNAs containing a high
degree of complementarity along the hairpin. These miR-
NAs are cleaved by Ago2 in the middle of the presumptive
passenger strand prior to Dicer processing [166]. This
nicking may facilitate strand selection and dsRNA
unwinding of some miRNAs. However, as Ago2 is the
only Ago family member with detectable endonuclease
activity, strand-selection must also occur without cleavage
of the passenger strand [167,168]. Following the loading
of Ago with the single-stranded guide miRNA, Dicer dis-
sociates and the effector complex (miRNP) capable ofCell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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selecting miRNA targets is formed through the association
of additional proteins [160,169].
Regulation of Dicer Activity
The relatively low levels of pre-miRNA relative to pri-
miRNA or mature miRNA suggest that Dicer is generally
very efficient at processing pre-miRNA [26,170]. In com-
parison to Drosha, which often requires the addition of
accessory factors to promote processing, regulation of
miRNAs at the Dicer step often involves inhibition of
Dicer activity. Early evidence for post-transcriptional con-
trol of miRNA at the level of Dicer processing comes from
studies of miRNA expression in colorectal neoplasia.
Mature miR-143 and miR-145 are expressed at much
lower levels in tumor samples than normal tissue. How-
ever, northern blots indicate that the level of pre-miR-143
or -145 is not significantly different in the tumor samples,
suggesting altered dicer processing in the colorectal tumor
samples [171]. Mature miR-143 and miR-145 are also
decreased in several cancer cell lines as well as in B-cell
malignancies [171,172]. These miRNAs act as tumor sup-
pressors through the repression of the mitogen activated
protein kinase ERK5 [173]. Although the mechanism of
processing control is unknown, these results suggest that
restoration of normal miRNA processing may represent a
novel therapeutic option for the treatment of some
tumors.
miRNA processing by Dicer is also differentially regulated
during normal development and tissue specification. For
example, while pre-miR-138 is ubiquitously expressed in
all tissues and HeLa cells, the mature miR-138 is only
detected in adult mouse brain and fetal liver [174]. An
alteration in nuclear export can be ruled out because the
precursor is effectively exported into the cytoplasm, sug-
gesting regulation of Dicer processing. Furthermore, while
pre-miR-138 is processed efficiently by Dicer in vitro, the
addition of HeLa cell extract inhibits the processing of pre-
miR-138. HeLa extract does not alter the processing of
other miRNAs normally expressed in HeLa cells [174].
These results suggest that HeLa cells, and most tissues,
express a yet-unknown factor which specifically inhibits
Dicer activity on miR-138.
In addition to inhibition of the Drosha processing step
discussed above, Lin-28 also inhibits the Dicer processing
of let-7 family members (Fig. 3) [125,175]. Lin-28 shut-
tles between the nucleus and cytoplasm, but is commonly
enriched within the cytoplasm, suggesting that the cyto-
plasm may be the primary location of the Lin-28:let-7
interaction. Addition of purified Lin-28 decreased the
association of let-7 with Dicer, and reduced Dicer-medi-
ated in vitro processing, suggesting that Lin-28 can com-
pete with Dicer for access to let-7 [125]. An additional
cytoplasmic blockade of let-7 processing by Lin-28 has
recently been described by Heo and colleagues (Fig. 3)
[176]. In hepatocellular carcinoma cell lines, Lin-28 pro-
motes the 3'-uridylation of pre-let-7 which inhibits Dicer
processing and promotes degradation of pre-let-7. This
activity requires the zinc-finger domains of Lin-28, as
mutations in this region maintain interaction with let-7
but do not induce uridylation [176]. The identity of the
uridylating enzyme recruited by Lin-28 awaits further
identification. Although Lin-28 promotes the uridylation
of only let-7 family members, it will be interesting to
determine if other pre-miRNAs are similarly regulated by
the addition of oligonucleotides.
Regulation of Dicer expression
The total levels of Dicer may serve as an important control
point in miRNA biogenesis. A careful analysis of the Dicer
5'UTR indentified multiple alternatively spliced leader
exons that are expressed in a tissue specific manner [177].
Although differential splicing alters the translation effi-
ciency of dicer in vitro, the biological relevance of alterna-
tively spliced dicer  isoforms is unknown. Altered
expression of Dicer is observed in several types of human
cancer, for example, Dicer is increased in prostate tumors,
as well as in a Burkitt's lymphoma derived cell line [178-
180]. Conversely, Dicer expression is decreased in non-
small-cell-lung cancer, and reduced Dicer correlates with
poorer prognosis [181]. These conflicting trends may be
indicative of cell type differences or tumor stage. Analysis
of precursor lesions of lung adenocarcinoma showed
increased Dicer expression, while advanced invasive ade-
nocarcinoma showed decreased protein levels [182]. The
importance of controlled Dicer levels in normal physiol-
ogy is further emphasized by the identification of let-7 tar-
get sites within dicer [8,183]. As the maturation of let-7 is
dependent on Dicer, this interaction represents a negative
feedback loop which may serve to regulate the total rate of
miRNA biogenesis (Fig 3).
Dicer may also be regulated post-transcriptionally. The
catalytic activity of Dicer processing of some miRNAs is
increased by removal of the amino-terminal helicase
domain, indicating that this domain may serve an autoin-
hibitory function [184]. In adult mouse neurons, the pro-
tease Calpain has been suggested to enhance Dicer
activity, perhaps indicating that the proteolytic removal of
the Dicer helicase domain could serve as a regulatory
mechanism in vivo [185]. Finally, association with TRBP
may activate Dicer by promoting the structural rearrange-
ment of the Dicer helicase domain [184,186]. A more
complete understanding of the regulation of Dicer activity
is an important challenge for future studies.
The role of Ago expression in miRNA regulation
The total levels of the Ago proteins within the cell also
contribute to global miRNA regulation and biogenesis.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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Ectopic expression of Ago1-4 resulted in a dramatic
increase of mature miRNAs [166]. In contrast, mouse
embryonic fibroblasts and hematopoietic cells from Ago2
knockouts showed reduced levels of all mature miRNAs
tested [166,187]. Some accumulation of pre-let-7 was
observed in Ago2 knockout cells, suggesting that the pres-
ence of Ago2 in the RLC may enhance Dicer cleavage
[166]. The dramatic increase in mature miRNA mediated
by increased Ago expression could also indicate that Ago
proteins are limiting and serve to stabilize miRNA. If this
is the case, one might expect that Ago protein levels may
be linked to the level of small RNA present within the cell.
Indeed, a retrospective study of publically available
microarray data from siRNA treated cells indicated an
increase in Ago2 mRNA independent of the siRNA
sequence [188]. Ago2 mRNA and protein expression was
also found to be increased in a subset of breast cancer
cells. Additionally, treatment with Epidermal Growth Fac-
tor (EGF) enhanced Ago2 stability, suggesting that altera-
tion of Ago2 levels can occur at both the transcriptional
and post-transcriptional level [189]. Recently, Ago pro-
teins have been identified as substrates of the α-(P4H-
α(I)) and β-(P4H-β) subunits of the type I collagen prolyl-
4-hydroxylase (C-P4H) [190]. The hydroxylation of Ago2
at proline 700 enhanced Ago2 stability, while knockdown
of the hydroxylating enzymes P4H-α(I) or P4H-β reduced
Ago2 protein level [190]. The P4H-α(I) subunit is rate-
limiting for the formation of active C-P4H and has been
reported to be up-regulated by a variety of factors, includ-
ing hypoxia and transforming growth factor-β. Given that
these treatments each induce many miRNAs, one could
hypothesize that concomitant up-regulation of Ago-2 by
C-P4H hydroxylation may serve to stabilize the newly syn-
thesized miRNAs.
RNA editing
Adenosine deaminases that act on RNA (ADAR) enzymes
catalyze the conversion of adenine to inosine (A to I) in
double-stranded RNA. The resultant inosine has biochem-
ical properties similar to guanosine and preferentially
base pairs with cytosine, therefore altering the base pair-
ing and RNA secondary structure of the edited RNA. Sev-
eral studies have demonstrated that pri-miRNAs and pre-
miRNAs are substrates of ADAR enzymes. The editing of
miR-142 alters the secondary structure of the pri-miRNA
and prevents cleavage by Drosha [191]. The edited,
unprocessed pri-miR-142 is then rapidly degraded by the
inosine-specific ribonuclease Tudor-SN [191]. miR-151 is
also edited by ADARs; editing can occur on either the pri-
or pre-miRNA species and prevents Dicer processing,
resulting in the accumulation of pre-miRNA hairpins
[192]. miR-151 editing occurs at high frequencies in a tis-
sue-specific manner, suggesting that differential editing
may underlie tissue-specific expression of some miRNAs
[192]. An analysis of 209 pri-miRNA sequences identified
47 which are highly edited in the human brain and in vitro
processing reactions indicated that while many edited pri-
miRNAs were refractory to processing by Drosha or Dicer,
the editing of selected miRNAs did not alter, or enhanced
processing [193]. If miRNA processing is unaffected, the
presence of edited nucleotides within mature miRNA
could shift the target specificity. For example, a single A-
to-I conversion within the seed sequence of miR-376
results in the regulation of PRPS1, an enzyme involved in
purine metabolism, which is not targeted by the un-edited
miRNA. ADAR2 null mice do not edit miR-376 and
PRPS1 is increased, suggesting that miRNA editing can
alter miRNA target selection in vivo [194]. Together, these
results indicate that the levels and/or targets of a sub-set of
miRNA can be post-transcriptionally regulated by A to I
editing.
Single nucleotide polymorphisms and mutations 
can alter miRNA processing
Similar to alteration of nucleotides by RNA editing, single
nucleotide polymorphisms (SNPs) and point mutations
within the pri-miRNA have the potential to alter the sec-
ondary structure and prevent processing of the pri-
miRNA. An analysis of chronic lymphocytic leukemia pri-
miRNA sequences identified mutations in 5 of 42 miRNAs
analyzed [36]. While 15% (75 total) of CLL samples
exhibited at least one mutation, no mutations were found
in 160 normal samples. A germ line cytosine-to-thymine
mutation 7 bp 3' to the pre-miR-16-1 region was associ-
ated with reduced mature miRNA levels [36]. In addition,
a common guanine/cytosine polymorphism within the
precursor of miR-146 is associated with increased risk of
papillary thyroid cancer [195]. The cytosine allele exhibits
reduced expression of mature miR-146 and results in an
increase in miR-146 targets compared to individuals with
the guanine allele. The SNP is located within the passen-
ger strand of miR-146 and the cytosine allele alters the sec-
ondary structure of miR-146 which inhibits Drosha
processing [195]. Similarly, a polymorphism within the
mature sequence of miR-125a disrupts Drosha processing
by introducing a bulge within the hairpin. Processing of
miR-125a could be restored by the introduction of a com-
plementary mutation on the passenger strand [196].
Together these studies emphasize the importance of sec-
ondary structure in the control of miRNA biogenesis.
Despite these examples, polymorphisms which disrupt
processing are likely to be rare. Large scale profiling exper-
iments have indicated that most miRNA SNPs occur out-
side of the pre-miRNA region. Those SNPs which are
present within the pre-miRNA are often considered to be
neutral because they occur within the loop region or con-
serve a bulged region [197,198]. This observation may
indicate that polymorphisms which alter miRNA process-
ing are detrimental to normal development and have
been selected against during evolution.Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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In addition to altering miRNA biogenesis, SNPs within
3'UTR of target genes may also perturb miRNA function
by introducing or disrupting binding sites. Allelic imbal-
ance sequencing of miRNA target genes containing SNPs
in the mouse suggests that polymorphic sites may be
responsible for the differential regulation of a surprisingly
large number of mRNAs (7.5–15%) [199]. Several physi-
ologically relevant examples of altered miRNA targeting
due to SNPs have been identified. For example, a SNP
within the let-7 binding site of the KRAS 3'UTR increases
the risk of non-small cell lung cancer by reducing let-7-
mediated repression of KRAS [200]. Additionally, a SNP
within the miR-24 binding site of dihydrofolate reductase
(DHFR) prevents miR-24 suppression, resulting in DHFR
overexpression and resistance to methotrexate based
chemotherapy [201]. As the identification of SNPs contin-
ues, it will be important to consider the introduction or
loss of miRNA targeting sites as potential functional con-
sequences of these small nucleotide changes.
Regulation of miRNA turnover
While the understanding of mechanisms which control
miRNA biogenesis has increased dramatically since the
discovery of miRNA, little is known about the mecha-
nisms which control degradation and turnover of miR-
NAs. In A. thaliana, the Small RNA Degrading Nuclease
(SDN) proteins degrade single-stranded miRNA, and
knockdown of these proteins results in widespread devel-
opmental defects [202]. To date, the animal homologues
which control miRNA degradation are unidentified. How-
ever, in vivo, miRNAs may be relatively stable since many
miRNAs persist following knockdown of miRNA process-
ing enzymes [203]. These studies also suggest that the deg-
radation of some miRNAs may be differentially regulated,
as the degree of reduction following Dicer knockdown
varies depending on the miRNA species [203,204]. As in
the case of miRNA biogenesis, the degradation of individ-
ual miRNA species is likely to be regulated. For example,
the stability of mature miR-29b, but not the co-tran-
scribed miR-29a, is modulated in a cell cycle-dependent
manner [205]. Extracellular stimuli which modulate the
degradation of specific miRNA have also been described.
Following hypoxia treatment, mature miR-199a, but not
miR-199a* is dramatically reduced in myocytes [206],
while in the liver, miR-122 is decreased within one hour
of interferon treatment [207]. The identification of factors
which regulate both general and specific miRNA turnover
represents an important challenge for future studies.
Post-transcriptional modifications of miRNAs may play
an additional role in the modulation miRNA turnover.
For example, the cytoplasmic poly(A) polymerase GLD-2
catalyzes the addition of a 3'-terminal adenosine follow-
ing Dicer cleavage and unwinding of miR-122 [208].
Mature miR-122 is reduced in GLD-2 null mice, suggest-
ing that the addition of a 3' adenosine promotes the sta-
bility of this miRNA [208]. Large scale sequencing of
cloned miRNA often indicates the presence of non-
genomically encoded residues on the 3' end of miRNA
[163,209]. Furthermore, the addition of either adenosine
or uridine has been appreciated to alter the stability of
both protein coding and non-coding RNAs, suggesting
that this mechanism of miRNA stability regulation may
extend beyond miR-122 [210].
Regulation of miRNA activity
Similarly to the control of total miRNA levels, the activity
of miRNA-mediated repression is highly regulated by
diverse factors. Following maturation, the mature miRNA
is loaded onto Ago proteins and associates with addi-
tional proteins to form the RISC complex. While a mini-
mal functional RISC complex can be generated in vitro
using recombinant Ago2 and small RNA [211]; proteom-
ics approaches have identified dozens of Ago associated
proteins, and the differential association of these proteins
allows for the modification of RISC activity [212]. For
example, members of the TRIM-NHL family of proteins,
including TRIM32 in mouse [213], and NHL-2 in C. ele-
gans [214], associate with RISC components and enhance
the activity of miRNA. Interestingly, sequencing of
TRIM32-associated miRNAs indicates that only a subset of
miRNAs, including let-7a, interact with TRIM32 (Fig. 3)
[213]. In addition to the TRIM-NHL proteins, Importin-8
(Imp8) has also been found to modulate miRNA-medi-
cated silencing through interaction with Agos. Knock-
down of Imp8 reduced association of miRNA with Ago2
and abrogated miRNA-mediated repression of endog-
enous miRNA targets [215]. These findings emphasize
that miR-mediated repression could be regulated by alter-
ations in the biogenesis as well as the activity of RISC-
associated miRNA. It is also of note that the association of
miRNA with specific RISC factors can result in increased
translation of target genes [216,217].
The biological function of miRNA can also be altered indi-
rectly by modification of the mRNA target site. For exam-
ple, mRNA binding factors which interfere with the
interaction of miRNA with target sites have been reported.
In the liver, cellular stress promotes the association of
HuR (ELAV1) with AU-rich elements present in the CAT-
1 mRNA [17]. This association antagonizes repression of
CAT-1 by miR-122 and allows increased CAT-1 protein
levels in response to stress stimuli [17]. miRNA repression
of target sites bearing conserved U-rich regions are simi-
larly antagonized by the RNA binding protein Dead end 1
(Dnd1) [218]. These findings suggest that miRNA-medi-
ated repression can be reversible, and the repression of
some mRNAs may be context-dependent. Finally, the abil-
ity of a miRNA to repress a given mRNA is limited by the
presence of miRNA binding sites within the 3'UTR. Alter-Cell Communication and Signaling 2009, 7:18 http://www.biosignaling.com/content/7/1/18
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native usage of cleavage and polyadenylation sites may
provide a simple mechanism for the tissue-specific regula-
tion of miRNA-mediated repression. Analysis of alterna-
tive 3'UTR isoforms indicates a global reduction of 3'UTR
length in proliferating cells [219], while differentiating
cells express mRNAs with longer 3'UTRs [220]. As short-
ened 3'UTRs contain fewer miRNA binding sites, mRNAs
in proliferating cells are more resistant to miRNA-depend-
ent repression [219]. It is speculated that the effects of
both (i) reduced expression of miRNAs, and (ii) increased
expression of mRNAs with shorter 3'UTRs may synergisti-
cally contribute to pathogenesis of some human diseases,
such as cancer.
Conclusion
miRNA are generated through the concerted action of
multi-subunit complexes which promote the sequential
cleavage, export, and loading of miRNA into silencing
complexes. An increasing number of reports suggest that
each of these steps serves as a potential point of regula-
tion, and therefore provides additional complexity to
miRNA-dependent gene regulation. Unlike transcrip-
tional regulation or post-translational regulation of pro-
teins, miRNA is able to modify not only gene expression
but also cellular function rapidly in response to environ-
mental cues. In particular, regulation of miRNA biogen-
esis may serve as the first line of response following
stimulation to promote the modulation of gene expres-
sion programs. Many of the mechanisms of miRNA regu-
lation are limited to a particular set of miRNA which
could allow the co-regulation miRNA in response to cellu-
lar stimuli. As a single miRNA modulates the expression
of many targets simultaneously, the co-regulation of sev-
eral miRNAs could have a dramatic impact on gene
expression and cellular physiology. In the future it will be
important to determine the mechanisms of miRNA co-
regulation, as well as the influence of such co-regulated
miRNAs on cellular processes.
As the altered expression of miRNAs has been implicated
in various human diseases, small molecules that modu-
late specific miRNA expression or activity are attractive
candidates for the therapeutic intervention of certain dis-
eases. For example, a small molecule screen for enhanced
silencing by miRNAs yielded a quinalone called Enoxacin
which increases the affinity of TRBP for RNA and pro-
motes RISC loading [221]. While Enoxacin may increase
the activity of miRNA in non-specific manner, a more
detailed understanding of mechanisms of miRNA regula-
tion may allow for the identification of small molecules
which specifically target a set of miRNAs. As more mecha-
nisms of microRNA regulation are uncovered, an impor-
tant challenge will be the elucidation of how multiple
mechanisms of miRNA regulation cooperate to orches-
trate the fine tuning of miRNA expression and function.
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